Companies › Inventera
1 active drug program in 1 registered trial: 1 Phase 3; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NEMO-103 Injection MR contrast agent for arthrography | – | Phase 3 | Rotator Cuff Tear | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07057037 | NEMO-103 Injection | Phase 3 | Rotator Cuff Tear | Other | Apr 2026 |
No annotated target.
–
Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.